Hester Biosciences Limited (NSE:HESTERBIO)
India
· Delayed Price · Currency is INR 1,762.80
+2.80 (0.16%)
May 22, 2025, 3:29 PM IST
Hester Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 3,111 | 3,045 | 2,661 | 2,350 | 2,143 | Upgrade
|
| Other Revenue | 39.24 | 66.48 | 121.14 | 116.41 | 33.64 | Upgrade
|
| Revenue | 3,150 | 3,112 | 2,782 | 2,466 | 2,177 | Upgrade
|
| Revenue Growth (YoY) | 1.23% | 11.86% | 12.80% | 13.30% | 15.94% | Upgrade
|
| Cost of Revenue | 883.23 | 997.28 | 824.81 | 678.19 | 527.1 | Upgrade
|
| Gross Profit | 2,267 | 2,115 | 1,957 | 1,788 | 1,650 | Upgrade
|
| Selling, General & Admin | 624.24 | 752.69 | 675.39 | 516.02 | 440.33 | Upgrade
|
| Other Operating Expenses | 993.03 | 758.94 | 654.62 | 536.16 | 478.27 | Upgrade
|
| Operating Expenses | 1,785 | 1,683 | 1,537 | 1,238 | 1,059 | Upgrade
|
| Operating Income | 481.74 | 431.29 | 420.28 | 550.43 | 591.22 | Upgrade
|
| Interest Expense | -127.03 | -91.19 | -51.49 | -25.76 | -60.62 | Upgrade
|
| Interest & Investment Income | - | 19.07 | 21.73 | 19.03 | 12.94 | Upgrade
|
| Earnings From Equity Investments | 41 | 46.09 | 44.09 | 4.23 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -94.68 | -29.92 | -4.59 | -4.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -3.1 | -3.31 | -9.57 | -5.42 | Upgrade
|
| EBT Excluding Unusual Items | 395.71 | 307.48 | 401.38 | 533.77 | 534.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.28 | 0.16 | 1.25 | 0.15 | Upgrade
|
| Other Unusual Items | - | 11.77 | - | - | -33.21 | Upgrade
|
| Pretax Income | 395.71 | 319.53 | 401.54 | 535.02 | 501.03 | Upgrade
|
| Income Tax Expense | 107.45 | 107.87 | 121.19 | 140.18 | 154.05 | Upgrade
|
| Earnings From Continuing Operations | 288.26 | 211.66 | 280.35 | 394.84 | 346.98 | Upgrade
|
| Minority Interest in Earnings | -13.38 | -22.77 | -14.08 | -1.64 | -2.68 | Upgrade
|
| Net Income | 274.88 | 188.89 | 266.27 | 393.2 | 344.3 | Upgrade
|
| Net Income to Common | 274.88 | 188.89 | 266.27 | 393.2 | 344.3 | Upgrade
|
| Net Income Growth | 45.52% | -29.06% | -32.28% | 14.20% | 18.03% | Upgrade
|
| Shares Outstanding (Basic) | 8 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | -4.65% | - | - | - | - | Upgrade
|
| EPS (Basic) | 33.89 | 22.20 | 31.30 | 46.22 | 40.47 | Upgrade
|
| EPS (Diluted) | 33.89 | 22.20 | 31.30 | 46.22 | 40.47 | Upgrade
|
| EPS Growth | 52.63% | -29.06% | -32.28% | 14.20% | 18.03% | Upgrade
|
| Free Cash Flow | 439.2 | 237.37 | -541.66 | -869.98 | 173.11 | Upgrade
|
| Free Cash Flow Per Share | 54.15 | 27.90 | -63.67 | -102.27 | 20.35 | Upgrade
|
| Dividend Per Share | 7.000 | 6.000 | 8.000 | 10.000 | 10.000 | Upgrade
|
| Dividend Growth | 16.67% | -25.00% | -20.00% | - | 51.52% | Upgrade
|
| Gross Margin | 71.96% | 67.95% | 70.35% | 72.50% | 75.79% | Upgrade
|
| Operating Margin | 15.29% | 13.86% | 15.11% | 22.32% | 27.16% | Upgrade
|
| Profit Margin | 8.73% | 6.07% | 9.57% | 15.94% | 15.82% | Upgrade
|
| Free Cash Flow Margin | 13.94% | 7.63% | -19.47% | -35.27% | 7.95% | Upgrade
|
| EBITDA | 649.76 | 599.98 | 624.22 | 712.92 | 720.33 | Upgrade
|
| EBITDA Margin | 20.63% | 19.28% | 22.44% | 28.90% | 33.09% | Upgrade
|
| D&A For EBITDA | 168.02 | 168.69 | 203.94 | 162.49 | 129.11 | Upgrade
|
| EBIT | 481.74 | 431.29 | 420.28 | 550.43 | 591.22 | Upgrade
|
| EBIT Margin | 15.29% | 13.86% | 15.11% | 22.32% | 27.16% | Upgrade
|
| Effective Tax Rate | 27.15% | 33.76% | 30.18% | 26.20% | 30.75% | Upgrade
|
| Revenue as Reported | 3,150 | 3,152 | 2,812 | 2,487 | 2,190 | Upgrade
|
| Advertising Expenses | - | 88.06 | 99.74 | 49.63 | 37.96 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.